Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655337 | 0.85 | — | — | |
| SCHEMBL4578588 | 0.82 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL506180 | 0.82 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL4899382 | 0.81 | — | — | |
| SCHEMBL8421787 | 0.79 | — | — | |
| SCHEMBL9211140 | 0.75 | ALDH1A1 (0.38) | TSHRTDP1 | |
| SCHEMBL6412213 | 0.75 | — | — | |
| SCHEMBL38270 | 0.75 | — | — | |
| SCHEMBL218909 | 0.75 | — | — | |
| SCHEMBL7917847 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390277-A1 | METHODS TO SENSITIZE TUMORS TO TREATMENT BY IMMUNOTHERAPY | OHIO STATE INNOVATION FOUNDATION | 2023-12-07 | — | — | US | disclosed |
| EP-3008037-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | Merck Patent GmbH (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2994467-A1 | ARYLQUINAZOLINES | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2953944-A1 | PYRIDAZINONE-AMIDES DERIVATIVES | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2920146-A1 | 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2831077-A1 | BICYCLIC PYRAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| WO-2014198372-A1 | HYDROXY-ETHYLENE DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014183850-A1 | ARYLQUINAZOLINES | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013143663-A1 | BICYCLIC PYRAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| EP-2622617-A2 | ELECTROLYTE FORMULATIONS | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012163480-A1 | ORGANIC ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012041437-A2 | ELECTROLYTE FORMULATIONS | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011103953-A1 | FLUORINE-FLUORINE ASSOCIATES | MERCK PATENT GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| CN-1863783-A | Compounds with Thrombopoietin Receptor Agonism | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005118545-A1 | GAS-PHASE OXIDATION OF ALKYL-SUBSTITUTED HETEROCYCLIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390277-A1 | METHODS TO SENSITIZE TUMORS TO TREATMENT BY IMMUNOTHERAPY | TXNRD2, PCK2, DLD | TSHR 4276/4885TDP1 1464/4885 |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | CYP4X1, CYP4Z1, CYP3A4 | TSHR 19/4885TDP1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.